Journal
ASIAN JOURNAL OF PSYCHIATRY
Volume 57, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ajp.2020.102512
Keywords
Attention deficit hyperactivity disorder; Pediatric; Prevalence; Prescription; Guanfacine
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology, Japan [19K07213]
- Grants-in-Aid for Scientific Research [19K07213] Funding Source: KAKEN
Ask authors/readers for more resources
The study revealed changes in prescription trends of ADHD medications for pediatric outpatients in Japan from 2012 to 2018, with a decrease in the prescription rates of methylphenidate-OROS and atomoxetine, while an increase in the prescription rate of guanfacine.
We aimed to clarify the prescription trend of ADHD drugs in Japanese pediatric outpatients. From January 2012 to December 2018, we evaluated the trends of prescribing methylphenidate-osmotic-controlled release oral delivery system (OROS), atomoxetine, and guanfacine as monotherapy. In boys, methylphenidate-OROS and atomoxetine prescriptions decreased from 46.5 % to 37.2 % and 18.6 % to 15.6 %, respectively. Prescriptions of guanfacine increased from 0.0 % to 12.3 %. In girls, the methylphenidate-OROS prescriptions was not significantly different (37.0 % to 26.4 %); however, atomoxetine decreased from 23.1 % to 16.3 %, and guanfacine increased from 0.0 % to 12.8 %. Methylphenidate-OROS and atomoxetine prescriptions changed to guanfacine between 2012 and 2018.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available